2025 Q2 -tulosraportti
147 päivää sitten0,084 SEK/osake
Viimeisin osinko
5,09%Tuotto/v
Tarjoustasot
First North Sweden
Määrä
Osto
5 465
Myynti
Määrä
12 222
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 676 | - | - | ||
| 824 | - | - | ||
| 1 086 | - | - | ||
| 1 430 | - | - | ||
| 27 | - | - |
Ylin
2,19VWAP
Alin
1,665VaihtoMäärä
2 1 046 134
VWAP
Ylin
2,19Alin
1,665VaihtoMäärä
2 1 046 134
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 414 302 | 414 302 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 414 302 | 414 302 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 H1 -tulosraportti | 21.8.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 H2 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sitten · MuokattuDoes anyone know what the rise is due to? 257% this past week..!
1 t sitten1 t sittenBased on the available information, the recent **200%+ surge in 2cureX’s stock price** does appear to be driven primarily by speculation and technical trading factors, rather than a specific, fundamental breakthrough or news event. Here’s a quick recap of the key points: - **No Major News Announcement:** There have been no reports of a sudden clinical trial success, new partnership, or unexpected regulatory approval that would justify such a dramatic price move. - **Low Float & High Volatility:** The stock’s low trading volume and market cap make it highly susceptible to rapid price swings based on trading activity alone. - **Technical Breakout & Momentum:** The “Strong Buy” technical signals and potential short covering (short squeeze) are likely amplifying the upward movement. - **Sector & Sentiment:** Biotech stocks, especially in oncology, can attract speculative interest, especially when traders anticipate future milestones (like the upcoming CE-IVDR approval for IndiTreat®). **In summary:** While the company’s long-term prospects hinge on its IndiTreat® platform and regulatory progress, the current price action is largely speculative. This kind of volatility is common in low-cap biotech stocks, where price movements can outpace actual business developments. Would you like to explore how to approach investing in such volatile stocks, or are you interested in monitoring specific upcoming milestones for 2cureX?
·25.10.2025Completely off the mark (maybe) ?? I had 2curex some time ago (sold in 2024) - now it just popped up again, and I became curious about the reasons for the price chart here in 2025. Can it really be true - as I may have concluded - that intellectual rights to Inditreat lie in the A/S - which were transferred from AB to some of the private shareholders for a little "pocket money" back in May. So the listed company is almost just a sales company - that can just go bankrupt - while all rights to Inditreat have been transferred (bought a bit cheaply) by some existing shareholders and founders. I think I have misunderstood something - otherwise it's a pretty clever maneuver, and then it seems that's what people have realized since the peak in June'2025.·8.12.2025I found this and I think you are right. https://www.2curex.se/newsroom/2curex-blog/ I have also written to 2cureX to get an explanation but have not received a reply since 1 Nov. Strategic Partnerships in Functional Precision Oncology: 2cureX AB has established a strategic partnership with 2cureX A/S to offer the IndiTreat® test through the Direct-to-Patient model. This innovative approach is now proven and expanding.
·27.8.2025I can't read anywhere that justifies the 7% drop we are experiencing today? At first glance, the stock looks good with an excellent opinion.. is there anyone who can provide an explanation 🤔
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
147 päivää sitten0,084 SEK/osake
Viimeisin osinko
5,09%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sitten · MuokattuDoes anyone know what the rise is due to? 257% this past week..!1 t sitten1 t sittenBased on the available information, the recent **200%+ surge in 2cureX’s stock price** does appear to be driven primarily by speculation and technical trading factors, rather than a specific, fundamental breakthrough or news event. Here’s a quick recap of the key points: - **No Major News Announcement:** There have been no reports of a sudden clinical trial success, new partnership, or unexpected regulatory approval that would justify such a dramatic price move. - **Low Float & High Volatility:** The stock’s low trading volume and market cap make it highly susceptible to rapid price swings based on trading activity alone. - **Technical Breakout & Momentum:** The “Strong Buy” technical signals and potential short covering (short squeeze) are likely amplifying the upward movement. - **Sector & Sentiment:** Biotech stocks, especially in oncology, can attract speculative interest, especially when traders anticipate future milestones (like the upcoming CE-IVDR approval for IndiTreat®). **In summary:** While the company’s long-term prospects hinge on its IndiTreat® platform and regulatory progress, the current price action is largely speculative. This kind of volatility is common in low-cap biotech stocks, where price movements can outpace actual business developments. Would you like to explore how to approach investing in such volatile stocks, or are you interested in monitoring specific upcoming milestones for 2cureX?
- ·25.10.2025Completely off the mark (maybe) ?? I had 2curex some time ago (sold in 2024) - now it just popped up again, and I became curious about the reasons for the price chart here in 2025. Can it really be true - as I may have concluded - that intellectual rights to Inditreat lie in the A/S - which were transferred from AB to some of the private shareholders for a little "pocket money" back in May. So the listed company is almost just a sales company - that can just go bankrupt - while all rights to Inditreat have been transferred (bought a bit cheaply) by some existing shareholders and founders. I think I have misunderstood something - otherwise it's a pretty clever maneuver, and then it seems that's what people have realized since the peak in June'2025.·8.12.2025I found this and I think you are right. https://www.2curex.se/newsroom/2curex-blog/ I have also written to 2cureX to get an explanation but have not received a reply since 1 Nov. Strategic Partnerships in Functional Precision Oncology: 2cureX AB has established a strategic partnership with 2cureX A/S to offer the IndiTreat® test through the Direct-to-Patient model. This innovative approach is now proven and expanding.
- ·27.8.2025I can't read anywhere that justifies the 7% drop we are experiencing today? At first glance, the stock looks good with an excellent opinion.. is there anyone who can provide an explanation 🤔
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
5 465
Myynti
Määrä
12 222
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 676 | - | - | ||
| 824 | - | - | ||
| 1 086 | - | - | ||
| 1 430 | - | - | ||
| 27 | - | - |
Ylin
2,19VWAP
Alin
1,665VaihtoMäärä
2 1 046 134
VWAP
Ylin
2,19Alin
1,665VaihtoMäärä
2 1 046 134
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 414 302 | 414 302 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 414 302 | 414 302 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 H1 -tulosraportti | 21.8.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 H2 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q2 -tulosraportti
147 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 H1 -tulosraportti | 21.8.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 H2 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
0,084 SEK/osake
Viimeisin osinko
5,09%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sitten · MuokattuDoes anyone know what the rise is due to? 257% this past week..!1 t sitten1 t sittenBased on the available information, the recent **200%+ surge in 2cureX’s stock price** does appear to be driven primarily by speculation and technical trading factors, rather than a specific, fundamental breakthrough or news event. Here’s a quick recap of the key points: - **No Major News Announcement:** There have been no reports of a sudden clinical trial success, new partnership, or unexpected regulatory approval that would justify such a dramatic price move. - **Low Float & High Volatility:** The stock’s low trading volume and market cap make it highly susceptible to rapid price swings based on trading activity alone. - **Technical Breakout & Momentum:** The “Strong Buy” technical signals and potential short covering (short squeeze) are likely amplifying the upward movement. - **Sector & Sentiment:** Biotech stocks, especially in oncology, can attract speculative interest, especially when traders anticipate future milestones (like the upcoming CE-IVDR approval for IndiTreat®). **In summary:** While the company’s long-term prospects hinge on its IndiTreat® platform and regulatory progress, the current price action is largely speculative. This kind of volatility is common in low-cap biotech stocks, where price movements can outpace actual business developments. Would you like to explore how to approach investing in such volatile stocks, or are you interested in monitoring specific upcoming milestones for 2cureX?
- ·25.10.2025Completely off the mark (maybe) ?? I had 2curex some time ago (sold in 2024) - now it just popped up again, and I became curious about the reasons for the price chart here in 2025. Can it really be true - as I may have concluded - that intellectual rights to Inditreat lie in the A/S - which were transferred from AB to some of the private shareholders for a little "pocket money" back in May. So the listed company is almost just a sales company - that can just go bankrupt - while all rights to Inditreat have been transferred (bought a bit cheaply) by some existing shareholders and founders. I think I have misunderstood something - otherwise it's a pretty clever maneuver, and then it seems that's what people have realized since the peak in June'2025.·8.12.2025I found this and I think you are right. https://www.2curex.se/newsroom/2curex-blog/ I have also written to 2cureX to get an explanation but have not received a reply since 1 Nov. Strategic Partnerships in Functional Precision Oncology: 2cureX AB has established a strategic partnership with 2cureX A/S to offer the IndiTreat® test through the Direct-to-Patient model. This innovative approach is now proven and expanding.
- ·27.8.2025I can't read anywhere that justifies the 7% drop we are experiencing today? At first glance, the stock looks good with an excellent opinion.. is there anyone who can provide an explanation 🤔
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
5 465
Myynti
Määrä
12 222
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 676 | - | - | ||
| 824 | - | - | ||
| 1 086 | - | - | ||
| 1 430 | - | - | ||
| 27 | - | - |
Ylin
2,19VWAP
Alin
1,665VaihtoMäärä
2 1 046 134
VWAP
Ylin
2,19Alin
1,665VaihtoMäärä
2 1 046 134
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 414 302 | 414 302 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 414 302 | 414 302 | 0 | 0 |